AbCellera Biologics has delivered 96% year-over-year revenue growth and beaten EPS estimates in 3 of the last 4 quarters, but the thesis hinges on whether the current cash burn — negative free cash flow at roughly 144% of revenue — narrows fast enough to allow quality metrics to recover; until it does, the stock remains speculative despite a favorable long-term risk/reward geometry.
Thesis pillars
- Industry Leading Revenue Growth→Stable
- Earnings Beat Consistency↑Improving
- Negative Fcf Quality Ceiling→Stable
- +1 more pillar — see the Why tab for full reasoning
AbCellera Biologics Inc. (ABCL) Stock Analysis
Range Bound setup · Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $6.49: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality.
AbCellera Biologics is a clinical-stage biotechnology company developing antibody medicines, with two internal candidates in clinical trials - ABCL635 for vasomotor symptoms and ABCL575 for atopic dermatitis - alongside a portfolio of royalty and milestone stakes from more than... Read more
Sell if holding. Engine safety override at $6.49: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality. Chart setup: RSI 41 mid-range, Bollinger mid-band. Score 5.9/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 17d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About AbCellera Biologics Inc.
About AbCellera Biologics Inc.
AbCellera Biologics, based in Vancouver, Canada, has two antibody drug candidates in clinical trials: ABCL635, a Phase 1/2 non-hormonal treatment for menopausal vasomotor symptoms with topline data expected in the third quarter of 2026, and ABCL575, a Phase 1 treatment for atopic dermatitis with data anticipated in the fourth quarter of 2026. The company held approximately $700 million in available liquidity as of December 31, 2025, following a $146.4 million net loss for the year.
Historically, AbCellera generated revenue by acting as a technology partner: since 2014 it started 104 partner-initiated antibody discovery programs, retaining downstream royalties and milestone payments as its partners advance drugs toward approval, with 19 molecules from its platform having reached the clinic. Since late 2023 the company has shifted focus toward its own internal pipeline, reducing new discovery partnerships while continuing obligations under existing multi-year agreements. In 2025 it completed a 130,000-square-foot clinical manufacturing facility in Vancouver, allowing it to control supply chain and manufacture drug substance in-house rather than relying on a contract manufacturing organization for early-phase trials. The company has also received CAD $475.6 million (US$347.9 million) in non-dilutive government financing from Canada and British Columbia since 2020, including CAD $300 million tied to an eight-year project supporting up to 17 internal programs through Phase 1 trials.
Show full overview
AbCellera's near-term investment case turns substantially on two early-stage binary readouts rather than diversified revenue: topline Phase 1/2 data for ABCL635 is expected in the third quarter of 2026 and Phase 1 data for ABCL575 in the fourth quarter, with two additional candidates, ABCL688 and ABCL386, not entering clinical trials until 2027. The 10-K notes the company does not anticipate generating sufficient revenue to achieve profitability until it either develops a drug independently or secures significant economic participation in a partner's approved product, leaving profitability contingent on outcomes still years away.
See also: Healthcare · Biotechnology
From AbCellera Biologics Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-20Recent Developments — AbCellera Biologics Inc.
Latest news
- NEWS Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price Target — benzinga Jul 7, 2026 positive
- NEWS Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration — benzinga Jun 17, 2026 positive
- NEWS Jazz Pharma And AbCellera Announce Preclinical Research Collaboration, Option And License Agreement To Discover, Develop — benzinga Jun 17, 2026 positive
- NEWS 12 Health Care Stocks Moving In Monday's After-Market Session — benzinga May 11, 2026 neutral
- NEWS AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate — benzinga May 11, 2026 positive
Generated 2026-07-20T05:32:10Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Material Events(8-K, last 90d)
- 2026-06-05Item 5.02LOWBoard appointed Victor Sandor as a new independent director effective June 1, 2026, serving until the next annual shareholder meeting. Routine board appointment; no departure or successor context involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.49: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 2.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 21%; Below-average business quality. Chart setup: RSI 41 mid-range, Bollinger mid-band. Prior stop was $6.01. Score 5.9/10, moderate confidence.
Take-profit target: $9.13 (+41.3% upside). Prior stop was $6.01. Stop-loss: $6.01.
Quality below floor (2.5 < 4.0).
AbCellera Biologics Inc. trades at a P/E of N/A (forward -9.2). TrendMatrix value score: 5.4/10. Verdict: Sell.
15 analysts cover ABCL with a consensus score of 4.1/5. Average price target: $11.
What does AbCellera Biologics Inc. do?AbCellera Biologics is a clinical-stage biotechnology company developing antibody medicines, with two internal...
AbCellera Biologics is a clinical-stage biotechnology company developing antibody medicines, with two internal candidates in clinical trials - ABCL635 for vasomotor symptoms and ABCL575 for atopic dermatitis - alongside a portfolio of royalty and milestone stakes from more than 100 historical partner-initiated programs. The company reported a $146.4 million net loss in 2025 against approximately $700 million in available liquidity, and has shifted its business model from a discovery-services partner to a company building its own drug pipeline.